Skip to content

Astra Covid Antibody Drug Works Against Omicron in Lab Tests

  • Antibody’s neutralizing activity same as from infection
  • Studies carried out by FDA, more tests being done by company
Japan Starts Coronavirus Booster Shots Amid Omicron Fears
Photographer: Noriko Hayashi/Bloomberg
Updated on

AstraZeneca Plc’s Covid-19 antibody therapy retained neutralizing activity against the omicron variant in lab testing in a sign the treatment should still provide protection against the pathogen.

The long-acting drug combination, which has been authorized for use in the U.S. for the prevention of the disease in high-risk people, produced the same neutralizing antibody levels found in someone who has been previously infected with the virus, the company said Thursday.